NextCure, a clinical-stage biotech developing next-gen cancer immunotherapies, raised $75 million by offering 5 million shares at $15, the midpoint of the range of $14 to $16.
NextCure plans to list on the Nasdaq under the symbol NXTC. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as lead managers on the deal.
